Summary
Sudden and/or arrhythmic death (SAD), which typically results from lethal ventricular arrhythmias (ventricular tachycardia and ventricular fibrillation, VT/VF) in the setting of coronary heart disease (CHD), afflicts an estimated 310,000 persons annually in the United States. Reductions in SAD have continued to lag those observed for other coronary heart disease (CHD) outcomes despite advances in resuscitation therapies and the use of implantable cardioverter-defibrillators (ICDs). Current approaches to SAD prevention remain centered on placing ICDs in patients with left ventricular ejection f